Rahul D. Ballal
CIK: 0001805097
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (19 total)
- Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.9K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.8K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15K shares- - Feb 12, 2026ELVN
Enliven Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
17.1K shares- - Aug 11, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.3K shares- - Jun 20, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.1K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15.8K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.8K shares- - Feb 6, 2025ELVN
Enliven Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
20.5K shares- - Nov 8, 2024AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct1.5K shares at avg. $59.21$89K - Nov 8, 2024AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct10K shares at avg. $25.99$260K - Nov 8, 2024AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct3.6K shares at avg. $57.24$204K - Nov 8, 2024AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct4.9K shares at avg. $58.57$289K - Nov 7, 2024AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct1.9K shares at avg. $54.41$102K - Nov 7, 2024AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct8.1K shares at avg. $53.32$434K - Nov 7, 2024AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct10K shares at avg. $25.99$260K - Oct 8, 2024ELVN
Enliven Therapeutics, Inc.
Sale(S)Direct10.4K shares at avg. $28.17$294K - Oct 8, 2024ELVN
Enliven Therapeutics, Inc.
Exercise(M)Direct4.1K shares at avg. $5.52$23K - Oct 8, 2024ELVN
Enliven Therapeutics, Inc.
Exercise(M)Direct6.3K shares at avg. $19.68$124K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,927 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,816 | - | $0 | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 14,950 | - | - | Direct |
| Feb 12, 2026 |  ELVN Enliven Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 17,126 | - | - | Direct |
| Aug 11, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,302 | - | - | Direct |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,120 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 15,768 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,816 | - | - | Direct |
| Feb 6, 2025 | ELVN Enliven Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 20,491 | - | - | Direct |
| Nov 8, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 1,500 | $59.21 | $88,815 | Direct |
| Nov 8, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 10,000 | $25.99 | $259,900 | Direct |
| Nov 8, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 3,571 | $57.24 | $204,404 | Direct |
| Nov 8, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 4,929 | $58.57 | $288,692 | Direct |
| Nov 7, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 1,868 | $54.41 | $101,638 | Direct |
| Nov 7, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 8,132 | $53.32 | $433,598 | Direct |
| Nov 7, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 10,000 | $25.99 | $259,900 | Direct |
| Oct 8, 2024 | ELVN Enliven Therapeutics, Inc. | Sale(S) | 10,420 | $28.17 | $293,557 | Direct |
| Oct 8, 2024 | ELVN Enliven Therapeutics, Inc. | Exercise(M) | 4,106 | $5.52 | $22,665 | Direct |
| Oct 8, 2024 | ELVN Enliven Therapeutics, Inc. | Exercise(M) | 6,314 | $19.68 | $124,260 | Direct |
1-19 of 19 transactions
About Ballal Rahul D.
Ballal Rahul D. (SEC CIK 0001805097) files insider reports with the SEC as Director of AGIOS PHARMACEUTICALS, INC. (AGIO) and Director of Enliven Therapeutics, Inc. (ELVN).
Signal8 holds 7 ownership filings by Ballal Rahul D., all Form 4s, filed between Oct 10, 2024 and Jun 23, 2026. Those filings report 19 transactions, from Oct 8, 2024 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Ballal Rahul D.'s filings is in CAMBRIDGE, MA.
Recent filings by Ballal Rahul D.
- Jun 18, 2026: Grant or award of AGIO derivative securities (Form 4, code A).
- Jun 18, 2026: Option exercise of AGIO shares (Form 4, code M).
- Jun 18, 2026: Grant or award of AGIO derivative securities (Form 4, code A).
- Feb 12, 2026: Grant or award of ELVN derivative securities (Form 4, code A).
- Aug 11, 2025: Option exercise of AGIO shares (Form 4, code M).
Other insiders filing for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Gheuens Sarah, Chief Medical Officer
- Backstrom Jay T., Director
- CAPELLO JEFFREY D, Director
- Foster-Cheek Kaye I, Director
- FOUSE JACQUALYN A, Director
- Ho Maykin, Director